Chugai Pharma (United States)

Recent papers from Chugai Pharma (United States)

1. Epitope-diverse autoantibodies induce neutrophil–epithelial niches driving kidney injury in ANCA-associated glomerulonephritisThe Journal of Experimental Medicine · 2026
2. Complement profiling and neutrophil single-cell analysis reveal inflammation via the classical complement pathway in Behçet’s syndromeInflammation and Regeneration · 2026
3. Exploiting Bridged Conformations for Precise Molecular Recognition in the Design of KRAS-Selective, Orally Available Macrocyclic PeptidesJournal of the American Chemical Society · 2026
4. Toward a more precise immunophenotypic and molecular definition of human cMoPsCell Reports · 2026
5. Efficient brain delivery and sustained retention of antibodies via dual targeting of blood–brain barrier and intra-brain proteinsmAbs · 2026
6. Recommendations for generating real-world evidence with regulatory-grade relevance and reliabilityInternational Journal of Clinical Oncology · 2026
7. Current State of Moderate Congenital Haemophilia A and the Need for Preventive TreatmentHaemophilia · 2026
8. Circulating effector memory CD8 + T-cells predict tumor shrinkage and reflect wasting conditions and immunity in tocilizumab plus gemcitabine/nab-paclitaxel for mPDACBMC Cancer · 2026
9. Highlights from the 17th Japan Bioanalysis Forum SymposiumBioanalysis · 2026
10. Human Pharmacokinetic Prediction of Antibody‐Drug Conjugates Using Human FcRn Transgenic MiceClinical and Translational Science · 2026
11. Anti-tumor activity of orally available cyclic peptide LUNA18 through direct pan-RAS inhibition across diverse RAS genetic alterationsMolecular Cancer Therapeutics · 2026
12. Adjuvant alectinib versus platinum-based chemotherapy in patients from Asia with completely resected ALK-positive non-small cell lung cancer (NSCLC): an exploratory subgroup analysis of ALINA including pharmacokinetics and safety in Japanese patientsInternational Journal of Lung Cancer · 2026
13. Review Article: Accelerating Coeliac Disease Clinical Trials—Beyond Celiac Meeting With Industry, Academics, Patients and the FDAAlimentary Pharmacology & Therapeutics · 2026
14. Absolute ¹⁹F-qNMR Quantification of Fluorinated Pharmaceuticals: Fluorometholone, Flurbiprofen, and FlutamideChemical and Pharmaceutical Bulletin · 2026
15. Polatuzumab Vedotin Enhances Intratumoral T‐Cell Infiltration and Demonstrates Combinatorial Efficacy With Anti‐CD20/CD3 Bispecific Antibody in a Syngeneic B‐Cell Malignancy Mouse ModeleJHaem · 2026
16. Risk factors for adverse events or use of high-potency corticosteroids in non-infectious uveitis: a Japan claims database study (J-CAT2)Immunological Medicine · 2026
17. T-cell chromatin states reflect individual differences in ex viv o cytokine release and cytotoxicity induced by T-cell engager ERY22 in cynomolgus monkeysToxicological Sciences · 2026
18. Development and validation of LC–MS-based bioanalytical methods for oligonucleotide therapeutics: points to considerDrug Metabolism and Pharmacokinetics · 2026
19. Safety and Efficacy of Satralizumab in Patients with Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD): Results from the Phase 3 METEOROID Trial (PL5.006)Neurology · 2026
20. A novel humanized FIX/FX hemophilia A mouse model for preclinical evaluation of FVIIIa-mimetic bispecific antibodiesBlood Advances · 2026